Bavencio 20 mg/mL concentrate for solution for infusion clinical trials
4 indexed studies · 0 currently recruiting
- AuthorisedPhase III and phase IV (Integrated)
Avelumab Short Maintenance Trial
This study looks at a medicine called Bavencio for bladder cancer (urothelial cancer). It aims to see if patients live longer (18 months or more) when receiving this medicine after initial treatment. It is a late-stage trial to understand more about its effects.
For: urothelial cancer · Bladder cancer · muscle invasive bladder cancerNetherlands - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A–BRAVE-Trial. ADJUVANT TREATMENT FOR HIGH-RISK TRIPLE NEGATIVE BREAST CANCER PATIENTS WITH THE ANTI-PD-L1 ANTIBODY AVELUMAB: A PHASE III RANDOMIZED TRIAL
This study is looking at a new treatment called Bavencio for a specific type of breast cancer (triple negative). It's a large study to see if adding Bavencio after initial treatment can help people live longer without their cancer coming back.
For: Breast CancerItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, single arm Study of avelumab in combination with Axitinib in Patients with unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy - AXAGIST
This study looks at a new combination of two existing drugs, avelumab and axitinib, for people with a type of cancer called Gastrointestinal Stromal Tumor (GIST). It's for patients whose cancer has come back or spread after standard treatments haven't worked.
For: Gastrointestinal Stromal Tumors (GIST)Italy · Poland - AuthorisedTherapeutic exploratory (Phase II)
Neoadjuvant AXITINIB plus AVELUMAB for patients with localized RCC and a moderate to high risk of recurrence (N17JAV)
This study is looking at a new combination of two drugs, axitinib and avelumab, for people with a common type of kidney cancer before surgery. The main goal is to see how well this drug combination shrinks the cancer.
For: renal cell carcinomaNetherlands